The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19

OBJECTIVES: Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the effectiveness of sofosbuvir in combination with...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Antimicrob Chemother
Main Authors: Eslami, Gholamali, Mousaviasl, Sajedeh, Radmanesh, Esmat, Jelvay, Saeed, Bitaraf, Saeid, Simmons, Bryony, Wentzel, Hannah, Hill, Andrew, Sadeghi, Anahita, Freeman, James, Salmanzadeh, Shokrollah, Esmaeilian, Hani, Mobarak, Morteza, Tabibi, Ramin, Jafari Kashi, Amir Hosein, Lotfi, Zahra, Talebzadeh, Seyed Mehdi, Wickramatillake, Aseni, Momtazan, Mahboobeh, Hajizadeh Farsani, Majid, Marjani, Sedigheh, Mobarak, Sara
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7529105/
https://ncbi.nlm.nih.gov/pubmed/32812051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkaa331
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki